Screening strategies for drug discovery-focus on ocular hypertension
Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics, Page: 91-117
2022
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
The vast number of eye diseases has necessitated a rigorous and concerted effort worldwide to find suitable drugs and other treatment modalities for these disorders. This has not been an easy task and required much research into the etiology of the ocular diseases, defining the targets for therapeutic intervention and then screening natural products or synthetic entities (small molecules or peptides, or antibodies) for affinity, potency, and selectivity for the desired target protein. In most cases, a testing funnel with defined acceptance criteria at each stage of screening using in vitro assays to help make Go/No-Go decisions is established and validated. Only agents that meet the prespecified criteria enter the next phase of testing, secondary assays followed by in vivo safety and efficacy studies. Such screening strategies eventually yield the lead compound which, after meeting investigational new drug-enabling criteria and specifications, subsequently enters clinical trials in human subjects.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/B9780128192917000393; http://dx.doi.org/10.1016/b978-0-12-819291-7.00039-3; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85143344793&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/B9780128192917000393; https://dx.doi.org/10.1016/b978-0-12-819291-7.00039-3
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know